Quince Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Gaia

• The Trade: Gaia, Inc. GAIA Director Paul Sutherland acquired a total of 1,000 shares an average price of $2.57. To acquire these shares, it cost around $2.57 thousand.
• What’s Happening: Gaia reported a wider-than-expected second-quarter loss.
• What Gaia Does: Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels-Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga.

Rise Gold

• The Trade: Rise Gold Corp. RYES 10% owner V B S Investments Pty Ltd acquired a total of 500,000 shares at an average price of $0.40. The insider spent around $200,000.
• What’s Happening: Rise Gold said Mr. Daniel Oliver Jr. has been appointed as a director of the Company.
• What Rise Gold Does: Rise Gold Corp is a mineral exploration stage mining company and its primary asset is a major past producing Idaho-Maryland Gold Mine property near Grass Valley, California, United States.

Quince Therapeutics

• The Trade: Quince Therapeutics, Inc. QNCX CEO Dirk Thye acquired a total of 88,000 shares at an average price of $1.26. To acquire these shares, it cost around $110,880.
• What’s Happening: Quince Therapeutics posted a narrower first-quarter loss.
• What Quince Therapeutics Does: Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases.

Check This Out: Top 5 Materials Stocks You May Want To Dump This Month

Don’t forget to check out our premarket coverage here